CN109820841A - Application of the resveratrol in preparation treatment Bronchial Epithelial Cells drug - Google Patents
Application of the resveratrol in preparation treatment Bronchial Epithelial Cells drug Download PDFInfo
- Publication number
- CN109820841A CN109820841A CN201910257491.0A CN201910257491A CN109820841A CN 109820841 A CN109820841 A CN 109820841A CN 201910257491 A CN201910257491 A CN 201910257491A CN 109820841 A CN109820841 A CN 109820841A
- Authority
- CN
- China
- Prior art keywords
- resveratrol
- application
- bronchial epithelial
- cell
- epithelial cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention discloses application of the resveratrol in preparation treatment Bronchial Epithelial Cells drug.The resveratrol has remarkable effect in the human bronchial epithelial cell survival rate of protection bivalent nickel ion induction, can be by the generation of regulation activity oxygen cluster, to reach the cellular damage for inhibiting bivalent nickel ion induction.The present invention induces the application in Bronchial Epithelial Cells prevention and treatment to provide new thinking for resveratrol in heavy metal.
Description
Technical field
The invention belongs to health food research and development technology fields, are specifically related to resveratrol in preparation and resist bivalent nickel ion
Induce the application in Bronchial Epithelial Cells.
Background technique
It is heavy metal-polluted to have a finger in every pie the environmental pollution as caused by heavy metal or its compound, mainly by mining, exhaust gas discharge, sewage
It irrigates and using caused by the human factors such as heavy metals exceeding standard product.Heavy metal cannot be degraded by microorganisms and can by food chain by
Grade transmitting enrichment, it is very big to human body and other biological potential threat.Since mankind's activity causes the content of beary metal in environment to increase
Add, exceeds normal range (NR), be directly detrimental to health and environmental quality is caused to deteriorate.Heavy metal can by breathing, gastrointestinal tract and
Skin is absorbed into human body, and the lung of human body is then acted on by transhipment and distribution.Therefore, heavy metal pollution, which has become, grinds
One of hot issue studied carefully.
Nickel and its compound are widely used in modern industry, for producing coin, jewelry, stainless steel alloy and battery etc..Nickel
(II) compound is classified as I class human carcinogen by international cancer research institution (IARC).Based on epidemiology, animal and cell
Level research, it has been found that nickel compound has pathogenic.Human body has extensive source, such as metal industry, plating to the contact of nickel
Technique and smoking etc..Nickel can be entered in vivo as a kind of compound by the mode that sucking, intake and skin absorb, and gradually be tired out
Product influences life and health.The molecular mechanism of nickel toxicity is considered being related to oxidative stress, DNA damage, and epigenetic changes, chronic inflammation
Disease and gene expression regulation.
Human bronchial epithelial cell is the first line of defence of respiratory apparatus confrontation destructive stimulus, is in acute and chronic airway disorders
Main is also one of the cell being damaged at first.Under normal physiological effect, human bronchial epithelial cell shows many
Biological function regulates and controls itself and flanking cell by autocrine and paracrine bioactive substance, not only has intracellular antioxygen
Change and bioconversion function, and the toxic damages of harmful substance can also be mitigated.However, the people when receiving extraneous sucking sexual stimulus
Bronchial epithelial cell can activate, and discharge a series of inflammatory mediator, cell factor, chemotactic factor (CF) and adhesion molecule induction
Damage.Therefore, finding and develop has the natural drug for resisting bivalent nickel ion induced damage, for the prevention of heavy metal damage
There is important meaning with treatment.
Even to this day, having in multiple fields uses polyphenol compound as the research report for preventing and treating drug.
Resveratrol is a kind of very strong natural polyphenol substance of bioactivity, is mainly derived from peanut, grape (red wine), tiger
The plants such as cane, mulberry fruit.More and more In vivo studies the result shows that, resveratrol has various oxidative stress and disease condition
Relaxation effect.Resveratrol is considered to have extensive effect good for health, including Cardioprotective, and neuroprotection is anti-oxidant, resists
Inflammation, antiproliferative and blood vessel formation against function.Therefore, the research and development of resveratrol have been to be concerned by more and more people.
In the prior art, protective effect machine of the resveratrol in bivalent nickel ion induction Bronchial Epithelial Cells
System has not been reported.
Summary of the invention
It is an object of the present invention to provide resveratrols in the Bronchial Epithelial Cells for inhibiting bivalent nickel ion induction
The application of protection.Resveratrol shields to the damage of bivalent nickel ion inducing cell, and the present invention protects cell associated injury
Shield regulatory mechanism and intracellular molecules level modulation mechanism are illustrated.
The technical solution adopted by the present invention are as follows: resveratrol is applied alone or treats human bronchial in preparation with other medicines combination
Application in epithelial cell damage drug.
Further, resveratrol is applied alone or draws with other medicines combination in preparation treatment Bronchial Epithelial Cells
The application in related disease drug risen.
Further, the Bronchial Epithelial Cells are the damages caused by bivalent nickel ion induction.
Further, resveratrol passes through the generation of regulation activity oxygen cluster, inhibits on bivalent nickel ion induction human bronchial
The damage of chrotoplast.
Further, the cellular damage includes: oxidative stress and/or inflammation.
Further, the related disease includes pulmonary fibrosis disease or Chronic Obstructive Pulmonary Disease.
Further, the dosage of resveratrol is 20~40 μM.
The invention has the following advantages:
The present invention provides the Bronchial Epithelial Cells that resveratrol induces bivalent nickel ion and shields, right
The relevant cellular inflammation factor and intracellular molecules level have regulatory mechanism, and it is anti-thin in preparation that the present invention provides resveratrols
Whole new set of applications in cellular damage and its drug of related disease.The Bronchial Epithelial Cells related disease of the induction
Are as follows: pulmonary fibrosis and chronic obstructive pulmonary disease etc..Resveratrol passes through the generation of regulation activity oxygen cluster, to reach inhibition nickelous
The expression of the cellular damage and relevant inflammatory factors of ion induction.The generation of the regulation activity oxygen cluster refers to, in resveratrol
Under effect, the reactive oxygen species of the induced generation of bivalent nickel ion are significantly reduced.
Detailed description of the invention
Fig. 1 is the generation of ROS in the BEAS-2B cell of mechanism of resveratrol inhibiting nickel ion damage；
Wherein, a: blank；B:0.2mM nickel；+ 20 μM of resveratrols of c:0.2mM nickel；+ 40 μM of resveratrols of d:0.2mM nickel.
Fig. 2 is damage of the mechanism of resveratrol inhibiting nickel ion to BEAS-2B cell survival rate.
Fig. 3 a is the generation that mechanism of resveratrol inhibiting nickel ion induces inflammatory factor TNF-α in BEAS-2B cell.
Fig. 3 b is the generation that mechanism of resveratrol inhibiting nickel ion induces inflammatory factor IL-1 β in BEAS-2B cell.
Fig. 4 is the activation of p38MAPK access in the BEAS-2B cell of mechanism of resveratrol inhibiting nickel ion damage.
Specific embodiment
Experimental material:
People's pulmonary branches tracheal epithelial cell (BEAS-2B): it is purchased from ATCC company, the U.S..
ROS fluorescence probe DCFH-DA: it is purchased from Sigma-Aldrich, the U.S..
Resveratrol: it is purchased from Chengdu Man Site Biotechnology Co., Ltd.
Nickel chloride (NiCl2): it is purchased from Shenyang traditional Chinese medicines Bioisystech Co., Ltd.
MTT: it is purchased from Shanghai starting experiment reagent Co., Ltd.
Real-time PCR kit: it is purchased from Kai Ji Bioisystech Co., Ltd.
BCA protein quantification assay kit: it is purchased from Beijing DingGuo ChangSheng Biology Technology Co., Ltd.
P-p38, p38 and β-actin antibody: it is purchased from Beijing Bo Aosen Bioisystech Co., Ltd.
Secondary antibody: it is purchased from CST Co., Ltd, the U.S..
Embodiment 1
1, mechanism of resveratrol inhibiting nickel ion damage BEAS-2B cell in ROS generation.
Method: people's pulmonary branches tracheal epithelial cell (BEAS-2B) of logarithmic growth phase is inoculated in 12 well culture plates, is placed on
37 DEG C, 5%CO2Being incubated overnight in cell incubator keeps its adherent.It is separately added into the resveratrol (20 and 40 μM) of various concentration,
Preculture 3h in the incubator is placed, the continuation of 0.2mM nickel is then added and is cultivated for 24 hours in incubator.Remove culture solution, PBS elution
Once, the good ROS fluorescence probe DCFH-DA of dilution of final concentration of 50uM is added, tinning paper, 37 DEG C of incubators are interior to incubate 45min.
After the fixed 30min of 4% paraformaldehyde room temperature, PBS is washed 3 times.After mounting processing, in fluorescence microscopy microscopic observation, as a result such as Fig. 1
It is shown.
Reactive oxygen species (ROS) are one of biological aerobic metabolism process byproducts, including oxonium ion, peroxide and are contained
Oxygen radical etc..Development of the ROS in multicellular organism, growth are broken up and play a crucial role in being proliferated.ROS is under normal conditions
The by-product of normal oxygen metabolism, maintains the baseline level of cell Proliferation and metabolism, key cells signal transduction molecule is adjusted, to guarantor
Body shape constancy is held to cut much ice.However, ROS level can sharply increase under extraneous factor effect, and active cell aoxidizes
Stress reaction, which induces cell apoptosis, even results in its necrosis.As shown in Figure 1, a is blank in Fig. 1, as shown in figure 1 shown in b, when with two
When valence nickel ion handles cell, intracellular ROS's is significantly raised horizontally relative to blank group.It is protected when resveratrol is added
When, as shown in figure 1 shown in c and d, when 20 μM of resveratrols and 40 μM of resveratrols is added, with the increasing of resveratrol additional amount
Add, the amount of ROS significantly reduces.
2, damage of the mechanism of resveratrol inhibiting nickel ion to BEAS-2B cell survival rate
Method: people's pulmonary branches tracheal epithelial cell (BEAS-2B) of logarithmic growth phase is inoculated in 96 well culture plates, is placed on
37 DEG C, 5%CO2Being incubated overnight in cell incubator keeps its adherent.It is separately added into the resveratrol (20 and 40 μM) of various concentration,
Preculture 3h in the incubator is placed, the continuation of 0.2mM nickel is then added and is cultivated for 24 hours in incubator.MTT (5mg/ml) 20 μ is added
Then 96 orifice plates are placed on 37 DEG C of constant incubators and continue to cultivate 4h by the hole l/.It after culture, discards supernatant, is added 150 μ l's
DMSO is completely dissolved first a ceremonial jade-ladle, used in libation crystal, surveys absorbance value (OD value) under 490nm wavelength, calculates cell growth according to absorbance
Proliferation rate, as a result as shown in Figure 2.
People's pulmonary branches tracheal epithelial cell is sensitive to ROS, is easy the damage by ROS, is carried out using Natural Antioxidants
Human bronchial epithelial cell protection is a kind of effective ways to keep its cell viability.From Figure 2 it can be seen that bivalent nickel ion damages
Group people's pulmonary branches tracheal epithelial cell survival rate is (80.03 ± 2.31) %, after the resveratrol of various concentration is added, with white
The increase of black false hellebore determining alcohol, BEAS-2B cell survival rate rise, and the survival rate of cell reaches when being handled with 40 μM of resveratrols
(95.03 ± 1.14) %.The result shows that resveratrol is to cell, there are protective effects.
3, mechanism of resveratrol inhibiting nickel ion induces the generation of inflammatory factor TNF-α, IL-1 β in BEAS-2B cell
Method is as follows: from 37 DEG C, 5%CO2People's pulmonary branches tracheal epithelial cell of logarithmic growth phase is taken out in cell incubator
(BEAS-2B), culture medium is sucked out, is directly added into 1ml Frizol, cell is blown down after standing 3-5min, is transferred to 1.5ml without RNA
In the EP pipe of enzyme.Be added 200ul chloroform (chloroform), be vortexed concussion at least 15s after with 4 DEG C of refrigerated centrifuges with
The speed of 12000rpm/min is centrifuged 15min, draws 500ul supernatant and 500ul isopropanol is added, mix room temperature 10min.Then
4 DEG C of centrifuges are centrifuged 15min with the speed of 12000rpm/min.Remove EP pipe in supernatant, be added 75% ethyl alcohol, blown with rifle it is even,
10min is centrifuged with the speed of 12000rpm/min with 4 DEG C of refrigerated centrifuges after vortex centrifugal.It is dry that supernatant air is drawn with pipette tips
It is dry, until waiting the precipitating color in EP pipe to become transparent from white, dissolved with 20ul DEPC water.It surveys and inhales under 570nm wavelength
Shading value (OD value).Reverse transcription is carried out after the RNA diluted concentration to 500ug/ml that extraction and determination is finished, and (RNA is changed into
CDNA), RT experiment is carried out according to kit requirement with obtained cDNA, as a result as shown in Figure 3a and Figure 3b shows.
In the patient with pulmonary disease, the expression of TNF-α and IL-1 β inflammatory mediator is significantly increased, such as Fig. 3 a
With shown in Fig. 3 b, when handling human bronchial epithelial cell with bivalent nickel ion, the table of IL-1 β and TNF-α inflammatory factor are found
It is increased up to amount is significant, when being protected with resveratrol, TNF-α and the decline of IL-1 β inflammatory mediator expression.Such as Fig. 3 a institute
Show, when 40 μM of resveratrol processing are added, the expression quantity of TNF-α inflammatory factor drops to 0.68 times of blank group.Such as Fig. 3 b
Shown, when 40 μM of resveratrol processing are added, the expression quantity of IL-1 β inflammatory factor drops to 0.46 times of blank group.
4, mechanism of resveratrol inhibiting nickel ion damage BEAS-2B cell in p38MAPK access activation
Method is as follows: cell pyrolysis liquid RIPA is carried out with inhibitors of phosphatases and PMSF according to the ratio of 100:1 respectively
Mixing, is placed in and is pre-chilled on ice.From 37 DEG C, 5%CO2Processed logarithmic growth as previously described is taken out in cell incubator
People's pulmonary branches tracheal epithelial cell (BEAS-2B) of phase, sops up old culture medium, and 1mL PBS is added, using scraper by Tissue Culture Flask
On cell scrape in parallel.5min is centrifuged with the speed of 2000rpm/min in 4 DEG C of refrigerated centrifuges, supernatant is sopped up, to cell
Configured cell lysate is added in precipitating and is blown and beaten using pipettor uniformly, every 15min vortex oscillation 1 time.Cell
After being cleaved 45min, 15min is centrifuged with the speed of 12000rpm/min in 4 DEG C of refrigerated centrifuges, draws supernatant in new
1.5mL is without in the EP pipe of RNA enzyme.According to BCA determination of protein concentration kit specification, after the protein concentration for measuring extraction, answer
Target protein expression situation is detected with Western Immuno imprinting techniques (western blot), as a result as shown in Figure 4.
P38MAPK participates in cell development and iuntercellular function and the various physiological processes such as synchronizes, and with inflammation, stress
The regulation of reaction is closely related.The ROS generated after oxidative stress activation can induce p38MAPK to activate.As shown in figure 4, when using
When bivalent nickel ion handles cell, the p38 expressing quantity of Intracellular phosphorylation is significantly increased relative to control group, when addition 20
When μM resveratrol or 40 μM of resveratrols are protected, the p38 expressing quantity of phosphorylation is significantly reduced.
By it is above-mentioned 1-4's the result shows that, resveratrol be able to suppress bivalent nickel ion induction human bronchial epithelial cell
The oxidative stress and inflammation of generation, and protect people's pulmonary branches tracheal epithelial cell vigor.
Claims (7)
1. resveratrol is applied alone or the application with other medicines combination in preparation treatment Bronchial Epithelial Cells drug.
2. application as described in claim 1, which is characterized in that resveratrol is applied alone or treats with other medicines combination in preparation
Application in related disease drug caused by Bronchial Epithelial Cells.
3. application as claimed in claim 1 or 2, which is characterized in that the Bronchial Epithelial Cells are by nickelous
Damage caused by ion induction.
4. application as claimed in claim 3, which is characterized in that resveratrol passes through the generation of regulation activity oxygen cluster, inhibits two
The damage of valence nickel ion induction human bronchial epithelial cell.
5. application as claimed in claim 1 or 2, which is characterized in that the cellular damage includes: oxidative stress and/or inflammation.
6. application as claimed in claim 2, which is characterized in that the related disease includes pulmonary fibrosis disease or chronic obstruction
Property lung disease.
7. application as claimed in claim 1 or 2, which is characterized in that the dosage of resveratrol is 20~40 μM.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910257491.0A CN109820841A (en) | 2019-04-01 | 2019-04-01 | Application of the resveratrol in preparation treatment Bronchial Epithelial Cells drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910257491.0A CN109820841A (en) | 2019-04-01 | 2019-04-01 | Application of the resveratrol in preparation treatment Bronchial Epithelial Cells drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109820841A true CN109820841A (en) | 2019-05-31 |
Family
ID=66873959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910257491.0A Pending CN109820841A (en) | 2019-04-01 | 2019-04-01 | Application of the resveratrol in preparation treatment Bronchial Epithelial Cells drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109820841A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113476430A (en) * | 2021-06-16 | 2021-10-08 | 东北农业大学 | Application of resveratrol in preparing medicine for treating oxidative function damage of porcine mammary gland epithelial cells caused by glyphosate |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102973546A (en) * | 2012-11-30 | 2013-03-20 | 中国人民解放军第四军医大学 | Application of acetyl-trans-resveratrol in preparation of medicine for preventing and/or treating pulmonary fibrosis diseases |
| CN107998110A (en) * | 2018-01-11 | 2018-05-08 | 上海市普陀区中心医院 | Resveratrol is used to prepare treatment or alleviates the purposes of chronic inflammatory airway disease medicine |
| CN109091470A (en) * | 2018-08-16 | 2018-12-28 | 辽宁大学 | Application of the flavonoid micromolecule compound in the oxidative stress diseases drug that preparation inhibits hexavalent chromium induction |
| CN111728962A (en) * | 2019-03-25 | 2020-10-02 | 泰州华元医药科技有限公司 | Resveratrol derivative and medical application of resveratrol derivative in anti-fibrosis |
-
2019
- 2019-04-01 CN CN201910257491.0A patent/CN109820841A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102973546A (en) * | 2012-11-30 | 2013-03-20 | 中国人民解放军第四军医大学 | Application of acetyl-trans-resveratrol in preparation of medicine for preventing and/or treating pulmonary fibrosis diseases |
| CN107998110A (en) * | 2018-01-11 | 2018-05-08 | 上海市普陀区中心医院 | Resveratrol is used to prepare treatment or alleviates the purposes of chronic inflammatory airway disease medicine |
| CN109091470A (en) * | 2018-08-16 | 2018-12-28 | 辽宁大学 | Application of the flavonoid micromolecule compound in the oxidative stress diseases drug that preparation inhibits hexavalent chromium induction |
| CN111728962A (en) * | 2019-03-25 | 2020-10-02 | 泰州华元医药科技有限公司 | Resveratrol derivative and medical application of resveratrol derivative in anti-fibrosis |
Non-Patent Citations (9)
| Title |
|---|
| JING WANG: "Resveratrol inhibits pulmonary fibrosis by regulating miR-21 through MAPK/AP-1 pathways", 《BIOMEDICINE & PHARMACOTHERAPY》 * |
| 周萍: "白藜芦醇对肺纤维化大鼠E-cadherin、α-SMA表达的影响", 《临床肺科杂志》 * |
| 张明灯: "白藜芦醇对慢性阻塞性肺疾病大鼠核因子κB的抑制作用", 《中国当代医药》 * |
| 张明灯: "白藜芦醇对慢性阻塞性肺疾病大鼠模型的保护作用", 《临床肺科杂志》 * |
| 李昶: "白藜芦醇对Ni2O3诱导NIH/3T3细胞氧化损伤保护作用的实验研究", 《中国公共卫生管理》 * |
| 李玉屏: "白藜芦醇减轻慢性阻塞性肺疾病大鼠内质网应激诱导的肺泡上皮细胞凋亡研究", 《中华结核和呼吸杂质》 * |
| 杜丽芬: "白藜芦醇对烟熏和脂多糖诱导大鼠慢性阻塞性肺疾病的改善及肺Derlin-1蛋白的调控作用", 《现代药物与临床》 * |
| 谭文乔: "白藜芦醇对镍精炼烟尘致大鼠肺组织ΔNp63 表达的干预", 《中国工业医学杂志》 * |
| 赵欣恰: "白藜芦醇对肺上皮细胞问质转化的影响及机制", 《中国科技教育》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113476430A (en) * | 2021-06-16 | 2021-10-08 | 东北农业大学 | Application of resveratrol in preparing medicine for treating oxidative function damage of porcine mammary gland epithelial cells caused by glyphosate |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Enhancement of amygdalin activated with β-D-glucosidase on HepG2 cells proliferation and apoptosis | |
| Yang et al. | Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by Antrodia camphorata | |
| da Costa Lopes et al. | Toxicological evaluation by in vitro and in vivo assays of an aqueous extract prepared from Echinodorus macrophyllus leaves | |
| Xia et al. | Mulberrin (Mul) reduces spinal cord injury (SCI)-induced apoptosis, inflammation and oxidative stress in rats via miroRNA-337 by targeting Nrf-2 | |
| WO2016072519A1 (en) | Differentiation-induced cell population from which undifferentiated cells have been removed, use of same, and method for producing same | |
| CN110731958A (en) | Application of EGCG in preparation of preparation for preventing and/or treating PRV infection and preparation for preventing and/or treating PRV infection | |
| CN109820841A (en) | Application of the resveratrol in preparation treatment Bronchial Epithelial Cells drug | |
| Wang et al. | Carbon dots up-regulate heme oxygenase-1 expression towards acute lung injury therapy | |
| Zhou et al. | Silencing of ADAM33 restrains proliferation and induces apoptosis of airway smooth muscle cells in ovalbumin‐induced asthma model | |
| CN105434326A (en) | Essence containing plankton and application of essence in cosmetics | |
| Zhou et al. | Lysosome-mediated mitochondrial apoptosis induced by tea polysaccharides promotes colon cancer cell death | |
| CN105801680B (en) | A kind of grouper piscidin4 polypeptide and its application | |
| Hu et al. | Oral administration of strontium gluconate effectively reduces articular cartilage degeneration through enhanced anabolic activity of chondrocytes and chondrogenetic differentiation of mesenchymal stromal cells | |
| Min et al. | Heme oxygenase-1 mediates cytoprotection against nitric oxide-induced cytotoxicity via the cGMP pathway in human pulp cells | |
| CN111658655A (en) | Application of cucurbitacin B in preparation of iron death inducer and anti-nasopharyngeal carcinoma drug | |
| CN109091470A (en) | Application of the flavonoid micromolecule compound in the oxidative stress diseases drug that preparation inhibits hexavalent chromium induction | |
| CN115177608A (en) | Application of long-chain acyl carnitine compound in preparation of medicine for preventing and/or treating liver cancer | |
| CN104981248A (en) | Anti-proliferative effects of palm vegetation liquor and extracts thereof in preventing pancreatic cancer | |
| CN114288297A (en) | Application of cepharanthine in preparation of anti-influenza virus medicine | |
| Theapparat et al. | Wound healing activity: A novel benefit of pyroligneous extract derived from pyrolytic palm kernel shell wood vinegar | |
| Gokduman | In vitro investigation of anti-cancer activity of propolis on hepatocellular carcinoma cells | |
| CN109223801B (en) | Novel gastric cancer tumor stem cell killing agent and application thereof | |
| Zhou et al. | Effects of pyrite bioleaching solution of Acidithiobacillus ferrooxidans on viability, differentiation and mineralization potentials of rat osteoblasts | |
| CN113521285A (en) | Application of intervention BOK in preparation of medicine for treating new coronary pneumonia | |
| Nagami et al. | Induction of apoptosis by hybrid liposomes for human breast tumor cells along with activation of caspases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190531 |